All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The FDA has approved Sanofi Pasteur Ltd.'s Dengvaxia vaccine to prevent dengue disease for children ages 9 through 16 with a previous dengue infection and who live in endemic areas of the U.S., including the territories of American Samoa, Guam, Puerto Rico and the U.S. Virgin Islands.